SCHEMBL2260227

SCHEMBL2260227

COc1ccc(C=CC(=O)Nc2cccc3ccccc23)cc1OC(C)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.60
MAOB P27338 1/20 0.60
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
RAB9A P51151 4/20 0.60
HPGD P15428 3/20 0.60
NPC1 O15118 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
ALDH1A1 P00352 2/20 0.60
TP53 P04637 2/20 0.60
CYP3A4 P08684 2/20 0.60
HIF1A Q16665 2/20 0.60
PKM P14618 2/20 0.60
NFKB1 P19838 2/20 0.60
CYP1A2 P05177 2/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
HSD17B10 Q99714 1/20 0.60
KDM4E B2RXH2 1/20 0.60
ABCC4 O15439 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260218 1.00 MAOA (0.60) MAOAMAOBMEN1KMT2ARAB9A
SCHEMBL2262767 0.88 MEN1 (0.53) MAOAMAOBMEN1KMT2ARAB9A
SCHEMBL2262760 0.88 MEN1 (0.53) MAOAMAOBMEN1KMT2ARAB9A
SCHEMBL2258947 0.87 MAOA (0.76) MAOAMAOBMEN1KMT2ARAB9A
SCHEMBL2258955 0.87 MAOA (0.76) MAOAMAOBMEN1KMT2ARAB9A
SCHEMBL2259875 0.83 ALDH1A1 (0.58) MEN1KMT2ARAB9AHPGDNPC1
SCHEMBL2259871 0.83 ALDH1A1 (0.58) MEN1KMT2ARAB9AHPGDNPC1
SCHEMBL2261272 0.83 MEN1 (0.53) MEN1KMT2ARAB9AHPGDNPC1
SCHEMBL2261276 0.83 MEN1 (0.53) MEN1KMT2ARAB9AHPGDNPC1
SCHEMBL2263009 0.82 MEN1 (0.62) MEN1KMT2ARAB9AHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2349982-B1 ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION CONGENIA S R L (IT) 2015-08-05 EP disclosed
US-8669261-B2 Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition Congenia SLR (IT) 2014-03-11 US disclosed
US-20130245019-A1 ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION CONGENIA SRL (IT) 2013-09-19 US disclosed
US-8470831-B2 Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition Cogenia SRL (IT) 2013-06-25 US disclosed
US-20110195977-A1 ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION CONGENIA SRL (IT) 2011-08-11 US disclosed
EP-2349982-A1 ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION Congenia S.r.l. (IT) 2011-08-03 EP disclosed
WO-2010049768-A1 ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION CONGENIA SRL (IT) 2010-05-06 WO disclosed
EP-2179984-A1 Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition Congenia S.r.l. (IT) 2010-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195977-A1 ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION AIFM1, TFAM, NDUFAB1 MAOA 537/4885MAOB 504/4885MEN1 4861/4885
US-20130245019-A1 ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION AIFM1, TFAM, NDUFAB1 MAOA 608/4885MAOB 549/4885MEN1 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.